Japan Liver Diseases Therapeutics Market Report 2022 to 2030

Japan Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Japan Liver Disease Therapeutics market will reach a value of $2.3 Bn from $1.4 Bn in 2022, growing at a CAGR of 6.2% during 2022-2030. Liver Disease Therapeutics in Japan is dominated by domestic pharmaceutical companies such as Aspen Pharmacare Japan, Mayne Pharma, and Phebra. The Liver Disease Therapeutics market in Japan is segmented into different types of disease and different therapy types. Some of the significant factors affecting the Japan Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10JPPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Vishwa Modhia

Buy Now

Japan Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Japan Liver Disease Therapeutics market will reach a value of $2.3 Bn from $1.4 Bn in 2022, growing at a CAGR of 6.2% during 2022-2030.

Japan is a high-income developed island nation in East Asia.

Japan has one of the highest rates of hepatitis C infection in the world, with an estimated 1.5-2 Mn people living with chronic hepatitis C. Antiviral medications for chronic hepatitis C are available, and these medicines have a high cure rate in Japan. Patients with chronic liver disease may also be eligible for the NHI system's Health Check-up and Guidance programme, which provides funds for frequent checks and counselling services to help them manage their illnesses.

According to the latest WHO data published in 2020 Liver Disease Deaths in Japan reached 14,195 or 1.29% of total deaths. The age-adjusted Death Rate is 4.78 per 100,000 population ranks Japan 164^th in the world. Japan's government spent 10.3% of its GDP on healthcare in 2020.

Japan Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Viral hepatitis is the leading cause of chronic liver disease in Japan, including liver cirrhosis. Japan has become one of the most successful countries in the world in terms of hepatitis virus elimination due to the availability of extremely potent antiviral medications in combination with anti-hepatitis measures. Japan is fortunate to be located in a rapidly expanding region. Japan has cutting-edge technologies as well as a diverse manufacturing industry. These aspects could boost Japan's Liver Disease Therapeutics market.

Market Restraints

Japan's population is ageing, and liver illnesses are more common in the elderly. This can impose a load on the healthcare system and limit people with liver illnesses' access to care. Japan is experiencing a labour shortage as well as a low immigration contribution, which is increasing the number of insecure workers. These factors may deter new entrants into the Japan Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Takeda Pharmaceutical Company: Takeda Pharmaceutical Company is a Japanese pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Entyvio and Vedolizumab
Astellas Pharma: Astellas Pharma is a Japanese pharmaceutical company that develops and produces a wide range of therapeutic products, including those for liver disease. Its liver disease products include Prograf and Advagraf
Daiichi Sankyo: Daiichi Sankyo is a Japanese pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Olmesartan and Micafungin
Mitsubishi Tanabe Pharma: Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Rebamipide and Tolvaptan
Eisai: Eisai is a Japanese pharmaceutical company that develops and produces a wide range of therapeutic products, including those for liver disease. Its liver disease products include Lenvatinib and Halaven

Recent Notable Updates

January 2023: Takeda and Arrowhead Pharmaceuticals released top-line results from the Phase 2 SEQUOIA clinical study of experimental fazirsiran for the treatment of alpha-1 antitrypsin deficiency-related liver disease. Takeda and Arrowhead also offered an overview of a Phase 3 trial, which was co-developed and would be undertaken by Takeda. Additional SEQUOIA study findings are scheduled to be presented at a future medical symposium and published.

Healthcare Policies and Reimbursement Scenarios

In Japan, the regulation and reimbursement of liver therapeutics are primarily overseen by the Pharmaceuticals and Medical Devices Agency (PMDA) and the National Health Insurance (NHI) system, respectively. The reimbursement process is managed by the Ministry of Health, Labour and Welfare, which determines which therapies are eligible for reimbursement and the conditions under which they will be covered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.